Thrombolytic Treatment After Acute Ischemic Stroke Results from the Minnesota Stroke Registry and Opportunities to Improve Care

Background:

We used data from the Minnesota Stroke Registry to examine rates of intravenous thrombolytic therapy in acute ischemic stroke and identifed opportunities to improve the utilization of this treatment.

Methods:

We analyzed a total of 1010 acute ischemic stroke patients who had been entered into the registry by 13 participating hospitals during the first three quarters of the 2008 calendar year.

Results:

Of the 1010 patients only 121 (12%) came within 2 hours of symptom onset. Intravenous recombinant tissue plasminogen activator (rt-PA) was administered to 32/55 (58%) of the patients who arrived within 2 hours of symptom onset and met eligibility criteria for this treatment. The remaining 66 patients had a documented reason for non-treatment. The most common reason (22/66) for non-treatment was rapid resolution of symptoms or mild stroke. Out of those 22 patients, 20 were ambulating independently prior to admission and only 9/20 (45%) ambulated independently at discharge